Figure 1.

Effects of omalizumab on clinical markers and corticosteroid sensitivity. Peripheral blood eosinophil counts (A), FENO (B), serum CCL4 levels (C), serum-soluble CD69 levels (D), and IC₅₀ values for dexamethasone on TNFα-induced CXCL8 production (Dex-IC₅₀) in PBMCs, a marker of corticosteroid sensitivity (E), were evaluated pre- and post-treatment with omalizumab. Individual values of the responder group (n = 19) and the non-responder group (n = 6) are shown; * p < 0.05, ** p < 0.01 (vs. pre-treatment).